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About the Canadian Research Initiative in Substance Misuse
Funded by the Canadian Institutes of Health Research (CIHR), the Canadian Research Initiative in 
Substance Misuse (CRISM) is a national research-practice-policy network focused on substance 
use disorders, comprising four large interdisciplinary regional teams (Nodes) representing British 
Columbia, the Prairie Provinces, Ontario, and Quebec/Atlantic. Each CRISM node includes regional 
research scientists, service providers, policy makers, community leaders, and people with lived 
experience of substance use disorders. CRISM’s mission is to translate the best scientific evidence 
into clinical practice, health services, and policy change. More information about CRISM can be found 
at: https://crism.ca.
About this Document
This document is one of a series of six national guidance documents, rapidly developed by the 
CRISM network at the request of the Government of Canada. Collectively, the six documents address 
urgent needs of people who use substances, service providers, and decision makers in relation to the 
COVID-19 pandemic. The urgent nature of this work required rapid development and dissemination 
of this guidance. This, and the continuing evolution of the knowledge base regarding COVID-19, 
precluded CRISM from conducting a comprehensive review of the relevant literature. However, when 
available, scientific evidence is cited in support of the expert advice offered herein.
The guidance provided in this document is subject to change as new information becomes available. 
Readers should note that the intent of this document is to provide general guidance rather than 
detailed procedural and logistical advice. Readers are advised to consult local public health and medical 
authorities for specific input on navigating their own unique regulatory and policy environments, as 
necessary.
The CRISM/COVID-19 guidance documents cover the following topics:
• Supporting People Who Use Substances in Shelter Settings during the COVID-19 Pandemic
• Telemedicine Support for Addiction Services (this document)
• Harm Reduction Worker Safety
• Recovery Environments
• Supporting People Who Use Substances in Acute Care Settings during the COVID-19 Pandemic
• Strategies to Help Individuals Self-Isolate for People who use Drugs
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Each document was developed by a core CRISM regional authorship committee, drawing on expert 
knowledge, available scientific evidence, and a review of relevant documentation from public health 
authorities. Draft documents produced by each authorship committee were reviewed by pan-Canadian 
panels of content and clinical experts, including people with lived and living experience of substance 
use.  A Directed Operating Grant provided funding for this work to CRISM from the Canadian Institutes 
of Health Research (CIHR).
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Disclaimer for Health Care Providers
The recommendations in this guidance document represent the view of the national guidance 
document authorship committee members and external reviewers, arrived at after careful 
consideration of the scientific evidence, available literature, and external expert peer review. The 
application of the recommendations in this guidance document does not override the responsibility 
of healthcare professionals to make decisions appropriate to the needs, preferences and values of an 
individual patient, in consultation with the patient (and their guardian(s) or family members, when 
appropriate) and, when appropriate, external experts (e.g. specialty consultation). When exercising 
clinical judgment in the treatment of opioid use disorder, healthcare professionals are expected to 
take this guidance document into account while upholding their duties to adhere to the fundamental 
principles and values of the Canadian Medical Association Code of Ethics, especially: compassion, 
beneficence, non-maleficence, respect for persons, justice and accountability, as well as the required 
standards for good clinical practice defined by relevant governing bodies within regional or local 
jurisdictions. Nothing in this guidance document should be interpreted in a way that would be 
inconsistent with compliance with those duties.
Legal disclaimer
While the individuals and groups involved in the production of this document have made every effort 
to ensure the accuracy of the information contained in this guidance document, please note that 
the information is provided "as is" and that CIHR and CRISM make no representation or warranty 
of any kind, either expressed or implied, as to the accuracy of the information or the fitness of the 
information for any particular use. To the fullest extent possible under applicable law, CIHR and 
CRISM disclaim and will not be bound by any express, implied or statutory representation or warranty 
(including, without limitation, representations or warranties of title or non-infringement).
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This document is intended to give an understanding of the growing role of telemedicine for healthcare 
access during the COVID-19 pandemic. This guidance document is not intended as a substitute for 
the advice or professional judgment of a healthcare professional. We cannot respond to patients 
or patient advocates requesting advice on issues related to medical conditions. If you need medical 
advice, please contact a local healthcare professional. 
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1.0  Key points of the guidance 
document
• This guidance document does not supersede a provider's clinical experience and decision-
making skills.
• Healthcare providers should use the same high-quality standards as in-person clinical care 
when using telemedicine for addiction services. They should aim to provide assessment and 
treatment of physical and mental health conditions and other drug use-related concerns, 
provide prevention, harm reduction and other health information and counseling, as 
appropriate.
• Patient consent must be obtained and documented during the telemedicine consultation, 
and healthcare providers must provide the limitations of telemedicine (ex. limited physical 
examination, limits in sound, image, and security breaches).
• Healthcare providers utilizing telemedicine should follow the same documentation guidelines 
as a regular consultation.
The following points pertain more specifically to opioid agonist therapy (OAT)
• Prescribers should assess and document safety concerns and measures to address them 
when prescribing any psychoactive substance, and in particular for methadone and sustained 
released oral morphine, as per Opioid Agonist Treatment Guidelines. 
• Prescribers must use clinical judgment to determine patient suitability for carries. Exceptional 
carries (beyond maximum carries allowed in guidelines) may be provided during the current 
pandemic due to specific circumstances and should be well justified and reassessed regularly. 
• Prescribers should explore alternative measures for witness dosing including virtual 
communication and observational methods.
• Safe storage and risk of carries as per Opioid Agonist Treatment Guidelines should be discussed 
and documented, and prescribers and patients should remotely agree and document a Safe 
Carry Agreement.
Telemedicine support for addiction services  | NATIONAL RAPID GUIDANCE  |   PAGE 11 
2.0  Purpose And Scope
On March 11, 2020, the World Health Organization declared COVID-19, caused by a novel coronavirus 
SARS-CoV-2, a pandemic, citing concern over alarming levels of spread and severity across the globe. 
The novel coronavirus has caused a national outbreak of respiratory infections in Canada since its 
discovery in December 2019. For most, this coronavirus causes only mild to moderate symptoms 
including fever and cough. However, people who use drugs (PWUD) have particular vulnerabilities that 
place them at risk of acquiring and transmitting SARS-CoV-2, such as poor housing and active addiction 
(factors that may make physical distancing challenging), as well as comorbid health conditions (e.g. 
COPD, HIV+) that may predispose to severe infection resulting in increased morbidity, mortality and 
healthcare system utilization. 
The COVID-19 pandemic spurred professional bodies and provincial/territorial jurisdictions to 
recognize and clarify the growing role of telemedicine for healthcare access in times of confinement. 
In reviewing existing telemedicine guidelines, it was found that they were somewhat restrictive and 
lacked specific information on how to effectively support and provide access to care for patients 
requiring addiction-related healthcare services. 
The purpose of this guidance document is to support healthcare providers to deliver telemedicine 
for addiction services during the COVID-19 pandemic. This document is intended to provide 
general guidance related to telemedicine focused on covering OAT and other addiction-related 
pharmacological treatments. It does not cover the use of telemedicine for non-pharmacological 
approaches. Furthermore, it does not provide guidance for specific populations or specific conditions, 
such as the comorbidity of mental health, pregnancy, or use in other populations.
2.1  INTENDED AUDIENCE
The target audience for this guidance document includes healthcare providers and pharmacists. The 
guidance contained in this document may also be relevant for policymakers, public health authorities, 
advocates, and other people working to support addiction services. 
2.2  DEVELOPMENT
The content and recommendations of this guidance document are based on a review of the literature 
focused on consensus practice regarding access to telemedicine for OAT, and was reviewed by 
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the authorship committee members and external reviewers, some of whom are OAT prescribers 
who have been involved with the development and incorporation of telemedicine in their respective 
institutions. Search terms (see Appendix 2) were used to identify relevant research evidence within 
jurisdictions where telemedicine for addiction and/or OAT is known to be in place (see Appendix 3). 
These jurisdictions are: Ontario, Quebec, Australia, United Kingdom (UK), France, and the telemedicine 
services supported by the World Health Organization (WHO). 
Recommendations were selected based on the general consensus for best practices found across the 
reviewed guideline and literature (referred to as 'best practice' in Table 1). A list of key points is also 
provided, based on common principles outlined in various guidance documents and expert opinions 
(referred to as 'consensus practice' in Table 1).
An independent CRISM committee of authorship committee members and external reviewers, made 
up of experts and people with lived and living experience from each regional CRISM node (n= 19), was 
assembled to participate and review this guidance document. The consensus of committee members 
was sought and secured through email and telephone communication, and tracked document review 
and revision. The draft guidance document and supporting materials were circulated to the committee 
for 2 rounds of review (May 4-12th, 2020), as well as a reviewer teleconference (May 8th, 2020). 
Feedback was collated and incorporated into a revised Version 1 Guidance Document.
2.3  DEFINITION OF TELEMEDICINE
We recognize that there are a number of terms used when referring to the use of information and 
communication technology to deliver healthcare. For the purposes of the following recommendations, 
the term “telemedicine” will be used as it is deemed to be the most relevant within the context of 
this report. We are basing this decision, using the definition for “telemedicine” set by the Federation 
of Medical Regulatory Authorities of Canada: “medical service provided remotely via information 
and communication technology.”2 While this guidance document does not distinguish between the 
type of telemedicine that exists (teleconsultation, tele-expertise, telemonitoring, or teleassistance),3 
healthcare providers must be consistent with their specific jurisdiction’s  regulations and guidelines. 
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3.0  Table 1: Summary of 








Telemedicine in General Practice
1. If the healthcare provider evaluates that telemedicine is appropriate, if the patient 
provides informed consent, and if both the healthcare provider and patient have the 
appropriate technological means, telemedicine can be practiced. The risks and benefits 
of providing care by telemedicine compared to providing care in-person should be 
assessed. 2-7, 10-14
Best Practice 11
2. The tools (telephone and video conferencing), platforms, and data used during 
telemedicine must be secured and respect the confidentiality of the consultation. 
Patient consent can be obtained verbally, unless written consent is required at the 
sign-up of the tool/ platform being used.3,4,6,7,11-13,15
Best Practice 8
3. Patient identification must be provided at each telemedicine consultation, including 
name and at least one of the following: date of birth, address, health card number, 
or other valid form of identification (which can also be displayed on the screen). The 
healthcare provider’s documentation should include the same elements as a regular 
note, while also indicating the reason and method for providing telemedicine.3,4,7,10,12
Best Practice 5
Use of Telemedicine during a Pandemic
4. During a pandemic, it is recommended that healthcare providers always consider 
using telemedicine to provide care, whenever possible. Each patient’s eligibility for 
telemedicine should be reviewed individually.4-7,9-13,16
Prescriptions should be transmitted verbally, electronically, by fax, or via 
secured electronic medical record (EMR) to protect pharmacists, patients, and 





Utilizing Telemedicine to Provide OAT during COVID‑19
5. The renewal/ re-induction of OAT is allowed by telemedicine, when indicated as per 
standard of care guidelines. OAT can be initiated by telemedicine in situations where 
the prescriber judges that a delay in the start of OAT would entail a risk for the patient, 
and if conditions are appropriate. All patients are encouraged to obtain a take-home 
naloxone kit. Information on how to use the take-home naloxone kit and training, along 





6. Healthcare providers should provide increased support to patients via remote 
methods and maintain ongoing and open communication. Online resources should be 
offered to patients, and increased counselling services by phone or other platforms 




7. Pharmacy delivery should be used if available, and authorized/ designated 
agents can be used to pick up or receive carries. Patients must have safe housing 
or safe storage for carries (i.e., a locked box). Virtual communication and other safe 
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4.0  Telemedicine
Recent developments in information and communications technologies (ICT) have made it possible 
for healthcare providers to practice medicine virtually and deliver medical services to areas where 
otherwise unavailable. As the delivery of telemedicine lends itself to potential violation of ethical 
obligations, such as professional secrecy, it is vital that telemedicine be used in ways that comply with 
current guidelines set out within each jurisdiction across Canada to protect the patients and clients 
that it seeks to serve.
4.1  TELEMEDICINE PROVIDERS
The healthcare provider using telemedicine must comply with their jurisdiction’s standard or policy. 
In some Canadian provinces, a license to practice telemedicine must be obtained. 
Healthcare providers using telemedicine services with patients outside their jurisdiction must comply 
with the laws and regulations of the territory in which the patients are located, in addition to the 
guidelines and policies of the providers' jurisdictions. The practice of telemedicine should be avoided 
where healthcare providers are likely to compromise the quality of their practice.
4.2  ASSESSING THE APPROPRIATE USE OF 
TELEMEDICINE 
Healthcare providers should use discretion in deciding which patients are appropriate for care by 
telemedicine. Providers must assess the risks and benefits of care given by telemedicine compared 
to care given in-person. Both the provider and the patient must have the appropriate technological 
means for telemedicine to occur. 
During a pandemic, the healthcare provider must also be cognizant of infection control considerations 
and consider the risk of contamination during a patient’s visit to the clinic, hospital, and/or pharmacy. 
Given this risk, a new patient, who is not known to the provider, can be evaluated via telemedicine, if 
deemed appropriate. 
During the COVID-19 pandemic, it is not necessary that a telemedicine consultation be done by the 
patient’s treating healthcare provider, although this is preferable.4
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4.3  TOOLS, PLATFORMS, PRIVACY, AND SECURITY
All tools (telephone and videoconferencing) and platforms used for telemedicine must be secured 
and must also respect confidentiality and privacy of all medical interviews and discussions with the 
patient. The healthcare provider is responsible for weighing the risks and benefits of using information 
and communication technology to carry out telemedicine. 
Examples of platforms that may be used during telemedicine include: 
• Those already included in properly secured electronic medical records (EMR);
• Those used by network establishments that have a telemedicine program; and,
• Secured telephone lines and/or direct dial toll-free (e.g. 1-800 number) and secured text 
messaging.
To maintain privacy and confidentiality, the physical environment of both the healthcare provider and 
the patient during the telemedicine session must be taken into account. Providers should conduct 
telemedicine in a quiet and enclosed room, whether in a home-office, or in a healthcare setting. 
Likewise, patients should be able to confirm that confidential information can be shared during the 
telemedicine session. Providers working from home should ensure that the storage and handling of 
patients' information is secured.
4.4  PROVIDER AND PATIENT IDENTIFICATION  
Healthcare providers should identify themselves at the beginning of each new consultation, by 
providing their name, title, professional licensing body and medical license number, and any relevant 
contact information if needed. The provider must then ask the patient to identify themselves, by 
providing their name, date of birth, address, and the province of the consultation. The provider may 
request the patient’s health card to be displayed on the screen for further identification. 
4.5  PATIENT CONSENT
Patient consent must be obtained at the beginning of the telemedicine session. The patient must 
understand the limitations of telemedicine and confirm that their setting is appropriate for exchanging 
confidential information. The healthcare provider must provide information regarding all possible 
technological limits, such as limits in sound, image, and security breaches, and the limits of medical 
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practice (ex. no physical examination).4 All verbal and written consent should be documented in the 
patient’s medical file.20 
4.6  DOCUMENTATION
Healthcare providers should enter notes in the patient’s medical file as soon as possible and should 
follow the same documentation guidelines as a regular consultation. The following details should also 
be included in the note:
• Technological means that have been used;
• The way in which the identification was made; and,
• The location of the patient during the telemedicine session (province and country).
Healthcare providers offering telemedicine services should have access to their EMR and should enter 
their notes there at the end of each meeting. 
During a pandemic, if a healthcare provider does not have access to their EMR, or if they are still 
using paper files, they must add their note to the medical file as soon as possible, while protecting 
the confidentiality of the data. The healthcare provider is responsible for keeping notes secure and 
confidential. Once the notes have been placed in a patient’s medical file, all other copies should be 
destroyed in a secure manner. 
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5.0  Telemedicine and COVID‑19
When possible, use of telemedicine services is highly encouraged during the COVID-19 pandemic, 
except where a physical examination or in-person test is required.
Healthcare providers should assess the feasibility of providing telemedicine services according to 
each patient’s needs and the risks of contamination due to clinic, hospital and/or pharmacy visits. 
Assessments can be an important source of support to patients who no longer have access to meetings, 
groups or counselling. Clinical judgment should apply when determining frequency of clinic visits.5
Although not specifically covered in the current version of this guidance document, telemedicine 
consultations should aim for the high standard assessment and treatment of physical and mental 
health conditions and other drug use-related concerns, provide prevention, harm reduction, and 
other health information and counseling, as appropriate. Telemedicine should also be utilized as a 
method to check on mental health status as comorbidity is high and mental health issues are often 
exacerbated during pandemic times. 
The following sections cover telemedicine in relation to pharmacotherapy.  
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6.0  Relaxation of Prescription 
Rules during COVID‑19 
Patients requiring addiction services often require medication in treating their addiction-related 
condition. This includes psychoactive medications that can be prescribed by telemedicine.
6.1  BENZODIAZEPINES AND PSYCHOSTIMULANTS
Provided that local licensing bodies do not object, the healthcare provider may prescribe 
benzodiazepines or psychostimulants to a previously known patient by telemedicine, as long as 
the provider ensures appropriate and timely follow-up, either in-person or by telemedicine (e.g. 
monitoring of weight and blood pressure in the case of a psychostimulant).4
In the case of a new patient, the healthcare provider is permitted to prescribe benzodiazepines or 
psychostimulants by telemedicine, if they judge and document in the medical file that it is medically 
indicated, following provincial guidelines and standards, and that a delay in initiating treatment will 
entail a risk to the patient. Appropriate and timely follow-up must be carried out, either in-person or 
by telemedicine. 
For all patients, the prescribed quantity must be safe and take into account the patient’s condition 
and the associated risks. Prescribers should document safety concerns and measures to address them 
when prescribing any psychoactive substance.
If the patient has a usual prescriber or primary care provider, ensure proper communication is provided 
to the usual prescriber or primary care provider regarding what was prescribed, and reasoning for it. 
6.2  OPIOIDS
Opioid prescriptions may be renewed following a telemedicine consultation, according to the 
professional judgment of the prescriber, if the prescribing provider:
• Is the patient’s treating provider;
• Is not the patient’s treating provider, but has access to the patient’s medical file kept by their 
treating provider; or,
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• Is not the patient’s treating provider, but has access to the patient’s medical records and can trace 
their previous prescriptions.4
The prescribed quantity of opioids must be safe (to an individual and the public) and documented, 
and be accompanied by appropriate and timely follow-up, either in-person or by telemedicine. 
For opioid renewal of a prescription or a new prescription, in the absence of a patient's medical 
file or records, the prescriber can prescribe only if the clinical situation warrants it and following 
provincial college guidelines. Opioid prescription in the context of opioid use disorder is covered in 
more details in the next section. If applicable, effort must be made to communicate a renewal or 
change in prescription to the patient’s usual prescriber or primary care provider. 
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7.0  Opioid Agonist Treatment and 
Telemedicine during COVID‑19
During the COVID-19 pandemic, it is essential that patients have continued and safe access to opioid 
agonist treatment (OAT) for their opioid use disorder. It is important to note that the following 
guideline should not supersede a provider’s clinical experience and decision-making skills. 
Healthcare providers should consider using telemedicine to provide continuous care for patients with 
opioid use disorder, taking into account each patient’s needs, the fundamental concerns of stability, 
safety, storage, overdose risk, diversion risk, lapse or relapse, the new dangers associated with 
COVID-19, and current public health advice around physical distancing.5 Providers should assume 
open, ongoing communication with patients. If it is not possible to provide care remotely, it may be 
more appropriate to continue in-person care. If performing a clinic in-person, then the clinic should 
follow the pandemic instructions given by their association, college, or Department of Health.
All decision-making processes should be recorded, including any deviations from these or standard 
guidelines, and clinical justifications should be made in the patient’s record. 
7.1  RENEWAL OF PRESCRIPTION/ RE-INDUCTION
The renewal of a prescription or the re-induction of OAT can be provided via telemedicine consultation 
if the healthcare provider can confirm the patient’s medication history on the medical file or record, 
and if the provider judges that this is justified by the patient’s condition and that previous therapy was 
well-tolerated (based on consultation with pharmacists). 
7.2  INITIATION OF OAT 
The initiation of OAT is authorized by telemedicine consultation only when the healthcare provider 
judges that a delay in the start of the treatment would entail a risk for the patient. 
Conditions necessary to initiate OAT by telemedicine:
• The provider has the necessary elements to make a relevant diagnosis or differential diagnosis, 
following the College's guideline and standards.
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• The provider obtains all relevant medical history, and a mental examination adapted to the 
situation occurs in a timely manner.
• The provider considers that a physical examination is not necessary or that it can be done 
later, in due time. An examination by a nurse can be done instead if the provider believes 
that all the tests performed by the nurse are sufficient for the moment. However, if a physical 
examination by a healthcare provider is deemed necessary in order to initiate and prescribe 
OAT, the provider will have to see the patient in-person to complete their assessment.
• The provider chooses the safest treatment under the circumstances and assesses the risks 
of toxicity, overdose and diversion of opioids, in relation to the treatment itself. When the 
provider does not have access to the patient's medical history or to information from a referent 
practitioner, OAT should be initiated at a low dose to begin and titrate up as per prudent OAT 
guidelines.
• The provider ensures that the patient has the necessary follow-up for their condition, 
either by telemedicine or in-person, while collaborating with the multidisciplinary team in 
place. The provider ensures that the required laboratory examinations, and if necessary, an 
electrocardiogram (ECG), are performed in a timely and feasible manner. 
• During this pandemic period, the provider must weigh the risk of COVID-19 transmission (e.g. 
to other patients in a clinical setting) versus potential risks of telemedicine (e.g. inability to 
undertake a physical examination or tests).18
7.3  CLINICAL ASSESSMENTS OF SUITABILITY FOR 
CARRIES 
OAT carries (i.e. take home dosing rather than daily witnessed ingestion) would enable healthcare 
providers to provide continuous care while ensuring that patients are safe in light of the COVID-19 
pandemic, by reducing their number of visits to the pharmacy and to the clinic. When conditions 
allow, and public safety concerns can be considered, patients may be provided with additional carries. 
Assessment of carries can be conducted using telemedicine. While applicable to the assessment 
of carries in general during COVID-19, this section covers specific guidance during telemedicine 
consultations.
Prescribers should use clinical judgment to determine whether the patient is suitable for carries. 
Urine drug detection samples (UDS) are not required for allowing carries. Prescribers should use 
clinical judgment to determine the maximum doses allowed for carries, in keeping with provincial 
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guidelines. OAT carries above the number allowed by guidelines to reduce risk for the patient during 
the COVID-19 pandemic should be justified and documented.
Given the inferior safety profile of methadone, patients with methadone carries are more likely to have 
respiratory depression and overdose than those with buprenorphine/ naloxone carries. Document 
that patient states they have the ability to safely store increased number of carries. Prescribers should 
continue their normal practice with respect to buprenorphine/ naloxone storage safety.
All healthcare providers should request that patients obtain naloxone overdose kits and become 
educated and trained on the use of naloxone. Lost or diverted methadone carries should be managed 
as per MMTG. Lost or diverted buprenorphine/ naloxone carries should be managed according to 
usual standard of care.
Patients may be considered suitable for carries if they have safe housing or safe storage (i.e. locked 
box). 
If available, pharmacists should deliver carries to the patient. If pharmacy delivery is not available, a 
reliable agent (e.g. a family member or friend) may be designated to pick up or receive the carries.
7.4  OBSERVED DOSES
Authorized prescribers should explore alternative measures to support witnessed dosing, including 
virtual communication and observation methods. Verification can be completed by asking the patient 
to speak after taking the dose.5,6 Witnessing the ingestion of carries may be difficult if the patient is 
isolating due to COVID-19 and the person delivering the carry dose does not have expert experience. 
Decisions regarding these cases should be taken on a case by case basis weighing risks and benefits. 
Extra precautions should be considered while managing observed doses in-person, such as handling 
and disposal of dosing cups, and reduced contact by not requiring signatures for dosing.17 Unless 
specified and required by the prescriber, the complete dissolution of the sublingual buprenorphine/ 
naloxone tablet does not need to be verified. 
7.5  BUPRENORPHINE/ NALOXONE
The choice of the OAT pharmacotherapy for patients newly assessed should follow best practices and 
evidence-based recommendations, with buprenorphine/ naloxone being suggested as the preferred 
option when appropriate.7
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Generally, doses of buprenorphine/ naloxone do not need to be witnessed, unless to address some 
specific clinical issue. Prescribers may prescribe up to four weeks of buprenorphine/ naloxone, in 
keeping with provincial guidelines.  Prescribers should use clinical judgment to determine whether to 
be progressive with carries (e.g. advancing from one to four weeks). 
Patients who are very stable may be assessed less frequently and be given carries for longer periods 
(e.g. every six to twelve weeks).5 
It may be possible and helpful to move appropriate patients from tablet sub/supra-lingual 
buprenorphine to depot buprenorphine.7 Whenever possible, maintain patients on Buvidal® Monthly 
or Sublocade® to reduce attendance.6
7.6  METHADONE
Given the inferior safety profile of methadone, patients with methadone carries are more likely to 
have respiratory depression and overdose than those with buprenorphine/ naloxone carries. It is 
therefore imperative to weigh the risks of community transmissions of COVID-19 against the risks of 
patient overdose death and the public health risk if methadone is used by someone other than whom 
the medication was prescribed.5
For those without carries, prescribers can introduce non-consecutive carries to reduce the frequency 
of pharmacy visits while reducing the risks of misuse/ diversion of larger amounts of methadone to 
patients without carries. Methadone safety should be assessed and documented, as per treatment 
guidelines. The suitability for consecutive carries should be considered based on risks, with, typically, 
up to a maximum of three consecutive doses treatment, and a maximum of six consecutive doses if 
the patient demonstrates stability. 
Methadone carries above the number allowed by guidelines to reduce risk for the patient during the 
COVID-19 pandemic should be assessed on a case by case basis, justified and documented.  
Advise patient that exceptional carries are being given due to current public health emergency. Discuss 
and document issues related to safe storage and risks of carries, including overdose and death, as per 
treatment guidelines.
A carry agreement should be remotely agreed to and documented in the chart.
At their observed doses, patients are seen by a pharmacist and assessed for sedation/ intoxication.
UDS are not required for low-risk patients but are required for higher-risk patients only if it will change 
clinical management. 
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Patients should not return used carry bottles at this time and should be advised and provided direction 
to ensure the used carry bottles are rinsed prior to disposal.8
7.6.1  New methadone starts
The initiation of methadone in methadone-naive patients requires a comprehensive assessment 
(virtual or in-person), and UDS should be done whenever possible.
Decision to prescribe methadone without UDS can only be made on a case by case basis and given 
that: i) the provider has the necessary elements to make a relevant diagnosis or differential diagnosis; 
and, ii) the provider assesses the safety of initiating methadone, the risks of toxicity, overdose and 
diversion of opioids, in relation to the treatment itself and provider communicates these risks to the 
patient.
Methadone initiation warrants more frequent clinical assessments, whether in-person or remotely. 
As a general rule, prescribers should consider waiting one month before initiating carries.5 If not 
possible, patients should at least collect or have delivered their medicine daily from the pharmacy in 
the first week, followed by carries that are documented and justified.6
7.6.2  Methadone restarts
Patients restarting treatment must complete a virtual or in-person assessment. 
7.7  SUSTAINED RELEASE ORAL MORPHINE 
Sustained Release Oral Morphine is an approved agonist treatment for opioid use disorder in Canada, 
and telemedicine can be used as for the other OAT medications.  
Sustained Release Oral Morphine is considered a high-risk substance for diversion.  Providers should 
follow established guidelines within their jurisdiction when initiating or following up patients on 
Sustained Release Oral Morphine while using telemedicine. 
Providers should use clinical judgment on a case by case basis and weigh benefits (e.g. reduced 
interactions in healthcare settings) and potential harms (e.g. risk of diversion) to adapt their practice, 
and before attributing additional carries during the COVID-19 pandemic. Patients should be followed 
and decisions should be reassessed regularly based on client response to care.
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7.8  PATIENTS WHO HAVE MISSED DOSES
Patients who have missed doses considered as an interruption of treatment (according to provincial 
guidelines) should restart after a virtual assessment, without a UDS, but usually starting at a lower 
dose.5,9
7.9  SAFETY AND DOCUMENTATION
The safety of using carries and issues related to safe storage should be assessed, documented, and 
discussed with patients. Prescribers should consider possible misuse or diversion and overdose risk 
and discuss harm reduction strategies with patients. All healthcare providers should discuss obtaining 
naloxone overdose kits and educate the patients in the use of naloxone. 
7.10  COMMUNICATION
Healthcare providers should provide increased support to patients via remote methods. Ongoing 
and close communication with prescribers is critical. Assessments can be an important source of 
support to patients who no longer have access to meetings, groups, or counselling. When a UDS is 
not required for carries, consider using technology to allow patients to connect with their provider 
without coming to the clinic. 
Healthcare providers should utilize this as an opportunity to educate and inform patients that unless 
necessary, in-person visits to the clinic or to pharmacies should be avoided. 
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8.0  Expanded Roles of Pharmacists
As a result of the pandemic, the roles and scope of practice of pharmacists have expanded. Health 
Canada has, under Section 56(1) of the Controlled Drugs and Substances Act (CDSA), issued 
temporary exemptions for prescriptions of controlled substances. This permits pharmacists to 
extend prescriptions, transfer prescriptions to other pharmacists, permit prescribers to issue verbal 
orders, and allow pharmacy employees to deliver prescriptions of controlled substances. Prescribers, 
pharmacists, and other healthcare providers are encouraged to work closely together to identify the 
best possible solution and outcome for patients. 
8.1  NON-PHARMACOLOGICAL PRESCRIPTIONS/ 
CONSULTATION REQUESTS
Documents related to non-pharmacological prescriptions/ requests for consultation must be 
transmitted securely to patients, for example via secured internet-type platforms, by fax, or directly 
by verbal order to designated professionals. 
8.2  PHARMACOLOGICAL PRESCRIPTION
Healthcare providers should respect standards relating to individual prescriptions. When refilling 
prescriptions, especially for a patient that the provider does not know, the provider must ensure that 
the medication is still required, that it is well-tolerated, and that the dosage is appropriate for the 
patient’s condition. 
During a pandemic, it is recommended to send prescriptions by one of the following methods:
• Verbal transmission from doctor or authorized healthcare provider to pharmacist;
• Fax transmission, including directly via EMR; or,
• Transmission by electronic means (e.g. secured platforms).
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8.3  PHARMACY DELIVERY 
For patients who are COVID-19 positive under isolation, or are at high-risk, symptomatic, and/or 
quarantined, or are presumed or confirmed COVID-19, pharmacists should deliver prescriptions to 
patients, if such service is available. If it is not available, appropriate precautions must be taken in 
order for the patient, the pharmacist, pharmacy employees, and pharmacy clients to maintain social 
distancing and avoid the dangers associated with COVID-19. 
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9.0  Resources for Providers and 
Patients
See Appendix 4 for further online resources on substance use
• Use health messages and materials developed by credible public health sources (e.g. public 
health, CDC).
• Post signs at entrances and strategic places providing instruction on handwashing and 
coughing, use of cloth face coverings, and social distancing.  For further guidance, please 
refer to other CRISM documents in this series, including: Harm Reduction Worker Safety, and 
Supporting People Who Use Substances in Emergency Shelter Settings.
• Provide educational materials about COVID-19 for non-French and non-English speakers or 
hearing impaired individuals.
 - Identify and address potential language, cultural, and disability barriers associated with 
communicating COVID-19 information to staff and patients.   
• Ensure communication with clients and key partners about changes in program policies and/
or changes in physical location.
• Identify communication platforms (e.g. hotline, automated text messaging, and websites) to 
help disseminate information inside and outside your organization. 
9.1  COUNSELLING FOR PATIENTS
Offer increased counselling services by phone or other platforms, with the intent of providing 
up-to-date medical information, reassurance, and mindfulness de-stressing where appropriate (see 
Appendix 4 for more resources).
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Appendix 1: Conflict of Interest 
Policy
Conflicts of interest were assessed using the Guidelines International Network’s Principles for 
Disclosure of Interests and Management of Conflicts.1 For this Guidance document, authorship 
committee members and external reviewers were required to disclose all sources and amounts of 
direct and indirect remuneration received in the past five years from industry, for-profit enterprises, 
and other entities (e.g. direct financial conflicts) that could introduce real, potential, or perceived 
risk of bias. In addition, authorship committee members and external reviewers were asked to 
disclose possible indirect conflicts of interest, such as academic advancement, clinical revenue, 
and professional or public standing that could potentially influence interpretation of evidence and 
formulation of recommendations. 
Before the draft guidance document was circulated for review, two CRISM staff members independently 
reviewed the disclosure forms to screen potential authorship committee members and external 
reviewers who should be precluded from participation due to ongoing or current financial relationships 
(e.g. employment, paid  consultancy or advisory board membership, stock ownership, intellectual 
property) with  industry or commercial entities that could theoretically benefit from the guidance 
document  recommendations. Consistent with the Institute of Medicine Standards for Developing 
Trustworthy Clinical Practice Guidelines,24 any individual with a current, ongoing relationship  with 
industry, who had received any remuneration or non-monetary support from industry  within the 
past 12 months, or with a history of significant remuneration or non-monetary  support from industry 
(defined for our purposes as cumulative receipt of more than $10,000  or equivalent value within 
the past five years), was excluded from participation on the guidance document prior to the review 
process. No authors nor contributors were excluded during initial screening as none met these criteria 
for exclusion.
Summary of disclosures 
No current or ongoing direct conflicts of interest were disclosed by the nineteen authorship committee 
members and external reviewers. Of the nineteen authorship committee members and external 
reviewers, three are CRISM staff. 
Of the nineteen authorship committee members and external reviewers, one disclosed receipt of 
funds prior to Guidance document involvement from a commercial entity (Indivior Inc.) that could 
theoretically benefit from Guidance document recommendations. Six authorship committee members 
and external reviewers acknowledged that their employment involved the delivery of OAT to patients. 
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Eight authorship committee members and external reviewers acknowledged their employment 
involved the support of delivery the OAT programs. Seven authorship committee members and 
external reviewers acknowledged their employment involved engagement in developing OAT practice 
within their respective organization. Two authorship committee members and external reviewers 
acknowledged that their employment involved engagement in developing telemedicine practice 
within their respective organizations. Two authorship committee members and external reviewers 
acknowledged that they have publicly stated the need for measures to increase OAT or Safe supply 
in general, and in the context of COVID-19. Receipt of research or program funding support from 
non-profit agencies or institutions was not considered a direct conflict of interest. On review, none 
of the disclosed direct conflicts of interest were deemed to be of sufficient weight or relevance to 
warrant exclusion from the Guidance document. 
Approximately 60% (n=11) of authorship committee members and external reviewers disclosed 
potential indirect sources of bias (e.g. specialization in addiction medicine, advisory board and 
committee membership, involvement with telemedicine programs, provincial OAT programs, previous 
guideline development, research interests). 
To mitigate the risk of bias while maximizing the contributions of members in their respective areas 
of expertise, authorship committee members and external reviewers were reminded to consider any 
influential factors or sources of bias during the review process. Authorship committee members and 
external reviewers with indirect potential sources of conflict contributed to review of sections related 
to their areas of expertise as well as the overarching guidance document content to ensure that a 
broad range of clinical and academic specializations was adequately represented. 24
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Appendix 2: Search Terms
• “COVID-19 Telemedicine Drug Users”
• “Telemedicine for People Who Use Drugs”
• “Opioid agonist therapy/ OAT COVID-19”
• “COVID-19 substance use”
• “COVID-19 Telemedicine OAT”
• “COVID-19 Telemedicine”
• “COVID-19 Telehealth”
• “COVID-19 Virtual Care”
• “COVID-19 Teleconsultation”
• “Virtual Care OAT”
• “Telemedicine OAT”
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See on next page (p. 33 - 39).
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REFERENCE Ontario Pharmacists Association 
(2020). Guide to Providing 
Virtual Care to Patients. Ontario 
Pharmacists Association. Link
Ontario MD (2020, March 
20). Virtual Care and the 
2019 Novel Coronavirus 
(COVID-19). OntarioMD. 
Link
Ontario MD (2020, April). 
Virtual Care: COVID-19 
Guide. OntarioMD. Link
Collège des médecins du 
Québec (2020, April 1).
Les téléconsultations 
réalisées par les médecins 
durant la pandémie 
de COVID-19. Guide à 
l’intention des médecins
Collège des médecins du 
Québec (2020, April 1).
La télémédecine réalisée 
par les résidents et 
moniteurs durant la 
pandémie de COVID-19. 
Guide à l’intention des 
superviseurs, des résidents 
et des moniteurs
Strengthening the Health 
Systems Response to 
COVID-19 Technical 
working guidance #1 
Maintaining the delivery 
of essential health 
care services freeing 
up resources for the 
COVID-19 response 
while mobilizing the 
health workforce for the 
COVID-19 response
The Royal Australasian College of 
Physicians (April 21, 2020)
Interim guidance for the delivery 
of medication assisted treatment 
of opioid dependence in response 
to COVID-19: a national response
NHS (2020, March 27). 
Clinical guide for the 
management of remote 
consultations and remote 
working in secondary care 
during the coronavirus 
pandemic. 
Ministère des Solidarités 
et de la Santé (2020, 
March 18). Recours à la 
téléconsultation dans le 
cadre de l’épidemie de 
coronavirus (COVID-19)
Ministère des 
Solidarités et de la 
Santé (2020, March 
18). Prise en charge 
hors COVID-19.
RELEASE DATE 2020 March 2020 April, 2020 March 2020 (last update 
April 2020)
March 2020 (last update 
April 2020)
April 2020 March 2020 March 2020 April 2020
WHEN AND WITH  
WHAT PATIENTS 
TO USE VIRTUAL 
CARE 
• COVID-19 positive patients 
or in self-isolation, elderly or 
vulnerable patients
• For patient’s understanding 
of medications and to resolve 
urgent medication management 
issues
• Witnessing the ingestion of OAT
• Demonstrating the use of a 
medical device
• Keep contact with 
patients with COVID-19 
symptoms
• Reassess patients 
virtually if worsening
• Avoid unnecessary trips 
to the office
• Manage chronic disease
• Managing other acute 
illness not requiring a 
physical exam
• Assess contamination 
risk of a clinic or ER visit
• Assess the feasibility 
of the teleconsultation 
according to patients’ 
needs and the risks and 
benefits.
Exception due to the 
pandemic, residents/
monitors (RM) can 
perform telemedicine with 
supervisor’s authorization.
Staff in quarantine with 
mild symptoms can 
take on remote tasks 
such as telemedicine, 
serving on a hotline to 
answer questions from 
concerned citizens, etc.
• Patients in OAT may require 
additional supports during 
periods of social isolation
• Regular monitoring and 
reviews of patients recognising 
the potential gaps in clinical 
assessment arising from lack 
of physical examination and/
or investigation (urine drug 
screens).
• Liaise with local and internet 
based services (e.g. online 
counselling, state/territory 
peer-based drug user groups) 
to assist clients during this 
time
• Provide clinicians with links for 
both Harm Reduction Services 
and Mental Health supports 
for clients
• For patients not 
requiring physical 
examination or test, 
and can communicate 
via phone or video
• Risk assessment 









on patients with 
COVID-19 symptoms
• Follow-up with 
patients infected 





when they deem 
it appropriate for 
their patient.










• PHIPA compliant virtual 
platforms, where patient 
consent is usually collected 
when they register for the 
service
• Video conferencing platforms, 
such as: 
- Skype and Teams by Microsoft 
- FaceTime by Apple 
- Zoom Basic 
- Google Hangouts 
- WhatsApp by Facebook
• Ensure privacy and security of 
data are maintained
• Develop policy on technologies 
and equipment to be used, 
privacy, obtaining patient 
consent, documentation 
procedures, response to a 
breach of confidentiality
• Most up-to-date version of 
encrypted applications and 
two-factor authentication 
with strong passwords where 
possible
• Any direct-to-patient 
telephone, telemedicine 
and video calling 
platforms
• Medical care virtual 
care platforms, such as: 




- Stand alone platforms
• Telephone calls 
and other video-
conferencing platforms 
- Skype and Teams 
(Microsoft) 
- Facetime (Apple) 
- Zoom.us 
- Google Hangouts, and 
others
• The tools and platforms 
used must be secure 
and must ensure the 
confidentiality of the 
interview
• For teleconsultations: 
- Platforms offered 




- Other teleconsultation 
platforms already used 
by medical institutions
• For prescriptions: 
verbal transmission to 
pharmacist, fax or EMR, 
electronic Dossier Santé 
Québec (DSQ) system
• The tools and platforms 
used must be secure 
and must ensure the 
confidentiality of the 
interview
• Phone calls
• For teleconsultations: 
- Platforms offered 
by the MSSS: Zoom 
Enterprise (also referred 




- Other teleconsultation 
platforms already used 
by medical institutions
• The platform cannot 
be determined by the 
monitor or the patient.
Standard telephone and special 




• Platform such as 
Attend Anywhere
• Teleconsultations that 
do not require the 
exchange of medical 
documents can be 
performed with any 
audio-visual platform 
(e.g. whatsapp, skype, 
Facetime)
• Each Regional 
Health Authority 
may chose best 




continued on next page
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IDENTITY 
VERIFICATION
Confirm identity of patient or their 
agent before providing virtual care
Patient identity:
• Patient’s health card 
displayed on the screen
• The patient’s file 
number (if applicable)
• The doctors must 
identify themselves 
providing: name, title, 
College of physician 
status and contact 
information if needed
• Patient must display 
his/her health card OR 
list the digits of his/her 
health insurance card # 
and their date of birth 
(telephone)
• Ask for the patient’s file 
number (if applicable)
Verify patient ID: checking 
date of birth, address, etc.
PATIENT CONSENT Obtain consent from the patient to 
receive care virtually and, if using 
an unregulated platform, consent to 
the privacy aspects of virtual care 
should be obtained & documented
Record verbal consent was 
obtained when using a 
product that does not have 
explicit health care consent
Unless you are using virtual 
care technologies where 
consent from the patient is 
handled at sign-up, ask for 
patient’s consent
• Obtain verbal consent 
from the patient to 
receive care virtually at 
the beginning of appt. & 
document this (patient’s 
file)
• Dr. must mention 
technological limits 
(sound, image, security 
breaches)
• Obtain verbal consent 
from the patient to 
receive care virtually 
at the beginning of the 
appointment
• R/M must mention the 
technological limits 
(sound, image, security 
breaches)
Take and record verbal 
consent
DOCUMENTATION Include the reason for providing 
virtual care services (e.g. “Due to 
COVID-19, patient in self-isolation”), 
the time, date, and technology 
used, and relevant information from 
the interaction
Clinical notes to record 
virtual visits
• Technology / 
telecommunication 
system used
• Means of identity 
verification
• Patient location during 
teleconsultation
• How consent was 
obtained (verbal or 
written)
Performed by R/M 
physically in their training 
institution (clinic/hospital):
• Add notes to patient’s 
file as usual with 
mention of the 
technology used
Outside the training 
institution:
• R/M must consult with 
supervisor on the best 
way to include notes to 
patient’s file
• R/M must keep a copy 
of the appointment 
notes until they’re 
properly added to 
the patient’s file. The 
R/M is responsible of 
destroying the copies 
once the file is complete
Document appointment 
notes and outcomes like 
face-to-face appointments
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REFERENCE CAMH/ META:PHI/ OMA (2020, 
March 22). COVID-19: Opioid 
Agonist Treatment Guidance. 
CAMH. Link
Centre for Addiction and 
Mental Health (2020, March 
27). Early Guidance for 
Pharmacists in Managing 
Opioid Agonist Treatment 
during the COVID-19 Pandemic. 
CAMH. Link
Karbi, J. and Brasch, J. 
(2020, March 28). A Harm 
Reduction Approach to 
Managing Opioid Use 
Disorder During COVID-19: 
A Brief Summary for 
Clinicians. CSAM. Link
Collège des médecins du QC, 
Ordre des infirmières du QC 
et l’Ordre des pharmaciens 
du QC. Lignes directrices TUO 
en lien avec la pandémie 
COVID-19 (temporaire). Link
Ordre des pharmaciens du 
Québec (2020, March 23). 
Substances désignées et 
activités professionnelles des 
pharmaciens - changements 
importants en contexte de 
pandémie. Link
The Royal Australasian College 
of Physicians (April 21, 2020). 
Interim guidance for the delivery of 
medication assisted treatment of 
opioid dependence in response to 
COVID-19: a national response. Link
Department of Health & Social Care 
(2020, April 15). COVID-19: Guidance 
for commissioners and providers of 
services for people who use drugs or 
alcohol. Government of UK. Link
Ministère des Solidarités 
et de la Santé (2020, April 
8). Prise en charge hors 
COVID-19. Link






• Pharmacy delivery should be 
used if available
• Virtual communication may 
be used to support witnessed 
dosing
• If pharmacy delivery 
unavailable, prescriber should 
closely coordinate patient 
attendance with pharmacy 
staff so that appropriate 
precautions can be taken
May release OAT doses to an 
authorized agent for pick up at 
the pharmacy or have the doses 
delivered
• Supply of TADs to a responsible 
carer from the dosing site
• Delivery of TADs to place of 
residence of isolated patient.
• Nominate an individual to collect 
the dispensed medicine on their 
behalf, with written instruction 
of the patient, but community 
pharmacies will receive guidance 
about acceptable alternatives 
during the pandemic. 
• If the patient cannot nominate 
someone a staff member may, 
with agreed authorization, be 










• Pharmacy delivery should be 
used if available
• Virtual communication may 
be used to support witnessed 
dosing
• All reasonable measures 
should be explored, including 
having a designated agent to 
pick up or receive the carries
• Practice may need to be 
modified on an individual 
basis and risk assessment
May release OAT doses to an 
authorized agent for pick up at 
the pharmacy or have the doses 
delivered
• Supply of TADs to a responsible 
carer from the dosing site
• Delivery of TADs to place of 
residence of isolated patient.
• Nominate an individual to collect 
the dispensed medicine on their 
behalf, with written instruction 
of the patient, but community 
pharmacies will receive guidance 
about acceptable alternatives 
during the pandemic. 
• If the patient cannot nominate 
someone a staff member may, 
with agreed authorization, be 






• Relates to social stability 
and an individual’s ability to 
manage carries safely
• Patients require safe storage 
for carries (i.e., a locked box) 
and safe housing
• Patients not suitable for 
carriers if: 
- Intoxicated or sedated when 
assessed 
- Unstable psychiatric 
comorbidity (acutely suicidal 
or psychotic)  
- Recent overdose 
- Currently using illicit 
substances in high-risk ways
• Patients who may not 
have been suitable carriers 
as defined by existing 
guidelines should be 
reassessed as per the 
COVID-19 -Opioid Agonist 
Treatment Guidance 
document during the 
COVID-19 pandemic
• Patients require safe 
storage for carries.
• Pharmacists should not 
make any changes to the 
dosage of existing therapy 
unless approved by  the 
prescriber
• Consider initiating 
or increasing carries 
if patient meets the 
following criteria: 
- Safe housing & safe 
storage (i.e. locked 
box) 
- No recent overdose 
- No high-risk use of 
illicit substances (e.g. 
concurrent alcohol or 
benzodiazepines, high-
dose IV opioid use) 
- Stable psychiatric 
comorbidities (i.e. not 
actively suicidal, no 
psychosis)
• Conduct a risk assessment for 
TAD provision and examine risk 
mitigation strategies. 
• Suggest use of checklists, or 
structured instruments such 
as the Australian Treatment 
Outcomes Profile
• Services should be transferring 
most, if not all, patients from 
supervised consumption to take-
home doses
• Where possible, patients may 
be provided with up to 2 weeks’ 
worth of take-home supply
• Those considered at most risk of 
diversion or misuse and overdose, 
or those living in shared or hostel 
accommodation where it is 
impractical or high risk to store 
large quantities of OAT medicines, 
may be required to pick up their 
medication daily or at another 
frequency. Consideration should 
be given to mitigations that 
reduce risk, such as hostel staff 
holding medicines, pharmacy 
delivery of medicines if available, 
lock boxes.
COVID‑19 & OAT/PWUD
continued on next page
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OBSERVED DOSES • Consider extra precautions, 
include care in the handling 
and disposal of dosing cups 
and reduced contact by 
not requiring signatures for 
dosing
• Explore alternative 
measures to support 
witnessed dosing, including 
virtual communication and 
observation methods
• Pharmacy delivery 
where available
• Virtual communication 
for supervised dosing 
where available
• For symptomatic and/
or COVID-19 positive 
patients, designate a 
reliable agent to pick 
up or receive carries
• Unless required by 
the prescriber, there is 
no need to verify the 
complete dissolution of 
the sublingual tablet or 
the taking of methadone 
- Verification can be done 
by asking patient to speak 
after taking the dose
• High: Patients commencing 
methadone or LS 
buprenorphine: Supervised 
dosing for at least 14 days 
methadone, 3-7 days SL BNX. 
Consider direct induction to 
depot buprenorphine without 
need for SL dosing. 
• High: with one or more of the 
following: High risk use of other 
sedative drugs
• Low risk recommendation: 
Methadone: 1 supervised dose 
& 6 TADs per week
BUP/ NAL • Perform clinical assessments 
of suitability for carries
• UDS not required for carries
• Witnessed dosing not 
required, unless to address 
some specific clinical issue
• May extend scripts up to 
4 weeks; prescriber to 
use clinical judgment to 
determine whether to be 
progressive with carries (e.g. 
advancing from 1-4 weeks)
• Very stable patients may be 
assessed less frequently (e.g. 
every 6-12 weeks)
• UDS not required
• Witnessed dosing not 
required
• May extend scripts up 
to 4 weeks
• Very stable patients 
may be assessed less 
frequently (e.g. every 
6-12 weeks)
• Newly assessed: should usually 
be offered buprenorphine as 
first choice and will be able 
to take away unsupervised 
titration doses for up to 2 
weeks. Those opting for 
methadone should collect 
their medicine daily from the 
pharmacy in the first week, 
followed by take-home doses.
• If only remote assessments are 
possible and drug testing is not 
possible, it may be possible to 
proceed with buprenorphine 
titration in known opioid-
dependent patients, based 
on an adequate history. This 
approach is unlikely to be 
suitable for methadone, where 
drug testing will usually be 
needed unless there is a clear 
history of opioid use and 
tolerance, in a known patient  
with evidence that opioids have 
been used in the last 24 hours.
• Unsupervised titration doses  for 
up to 2 weeks 
• It may be possible and  helpful to 
move a small  number of patients 
from daily  (or less frequent) 
• sub/supra-lingual bup to  depot 
bup.  
continued on next page
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METHADONE • Greater concerns with 
respiratory depression and 
overdose than bup/nal 
carries. Thus, the risks of 
community transmissions of 
COVID-19 must be weighed 
against the known risks 
of overdose death due to 
diversion to the community 
or to overuse of methadone 
carries by the patient
• Non-consecutive carries are a 
way of reducing the frequency 
of pharmacy and the risks of 
misuse/diversion of larger 
amounts of methadone. At 
their observed doses, patients 
are seen by a pharmacist 
and assessed for sedation/ 
intoxication
• New methadone starts: 
initiated in methadone-
naive patients after a 
comprehensive assessment 
(virtual or in-person), 
including a UDS. This 
warrants more frequent 
clinical assessments, whether 
in-person or remotely. 
Consider waiting one month 
before initiating carries. 
• Methadone restarts: 
Complete a virtual or 
in-person assessment and 
offer bup/nal as a preferred 
treatment option. If a 
patient wishes to restart 
methadone and a UDS cannot 
be performed, prescribers 
should consider using a lower 
starting dose of methadone.
• Patients who have missed 
doses (i.e. up to 7 missed 
doses of methadone or 14 
missed doses of bup/nal): 
restart after an assessment 
(virtual), without a UDS.
• Consider delivering 
a smaller number of 
methadone carries at one 
time to enhance patient 
safety. E.g. if patient is 
authorized to receive 13 
carries, deliver 6-7 doses 
weekly
• Advise patients that the 
return of used carry bottles 
is not recommended at this 
time, and provide direction 
to ensure the used carry 
bottles are rinsed prior to 
disposal
• More caution required 
due to higher risk 




• UDS not required 
for low-risk patients; 
required for higher-
risk patients only if 
it will change clinical 
management
• Consider suitability 
for consecutive carries 
dependent on risk, 
up to a maximum 
of 3 consecutive 
doses (see META:PHI 
“Carry Ladder” during 
COVID-19)
New methadone starts: should 
generally collect their medicine daily 
from the pharmacy in the first week, 
followed by take-home doses.
Methadone restart: People 
restarting treatment who were taking 
methadone no more than 7 days ago 
may be able to return to methadone 
after careful assessment but usually 
starting at a lower dose, titrated up 
again and with only 2 to 3 days pick-up 
to start.
continued on next page
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COMMUNICATION • Verify contact information for 
all patients
• Provide increased support to 
patients via remote methods
• Provide contact information 
to pharmacy colleagues to 
troubleshoot clinical scenarios 
as they arise
• Inform patients of your clinical 
decision. Explain the need to 
avoid in-person visits unless 
absolutely necessary
• Virtual communications: 
opportunity to inform, 
educate, and model physical 
distancing
• Offer online resources to 
patients
• Offer increased counselling 
services via remote 
methods, with the intent of 
providing up-to-date medical 
information, reassurance and 
mindfulness
• Assessments can be an 
important source of support 
to patients who no longer 
have access to meetings, 
groups or counselling. When a 
UDS is not required, consider 
using technology to allow 
patients to connect with their 
provider remotely
Ongoing and close 
communication with prescribes 
is critical. Pharmacists’ 
assessments are valuable, 
particularly for decisions related 
to suitability for progressive 
carry doses.
Inform GPs of the changes in 
prescribing and amounts of OAT 
stored in homes where there are 
children, inform local children’s social 
care services if they are involved or if 
there are concerns
• Stay updated on local level 
of transmission of COVID-19 
through your local and state 
health departments.
• Use health messages and 
materials developed by credible 
public health sources, such as 
your local and state public health 
departments or the Centers for 
Disease Control and Prevention 
(CDC).
• Post signs at entrances and 
in strategic places providing 
instruction on hand washing 
and cough, use of cloth face 
coverings, and social distancing.
• Provide educational materials 
about COVID-19 for non-English 
speakers or hearing impaired
• Keep staff and clients up-to-
date on changes in facility 
procedures.
• Ensure communication with 
clients and key partners about 
changes in program policies and/
or changes in physical location.
• Identify communication 
platforms (e.g. hotline, 
automated text messaging, 
websites) to help disseminate 
information to those inside and 
outside your organization. 
• Identify and address potential 
language, cultural, and 
disability barriers associated 
with communicating COVID-19 
information to workers, 
volunteers, and those you serve. 
Learn more about reaching 
people of diverse languages and 
cultures.
continued on next page
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• Methadone carry safety 
should be assessed and 
documented, as per MMTG
• Consider possible misuse or 
diversion and overdose risk
• Advise patients that 
exceptional carries are being 
given due to current public 
health emergency, and MMTG 
standards will reapply once 
it is over
• Discuss and document issues 
related to safe storage and 
risk of carries, including 
overdose and death
• Document that patient states 
they have the ability to safely 
store increased number of 
carries
• Patients should be directed 
to obtain naloxone overdose 
kits and educated in the use 
of naloxone
• A carry agreement should 
be either signed or remotely 
agreed to and documented in 
the chart
• Lost or diverted methadone 
carries should be managed as 
per MMTG. Lost or diverted 
bup/nal carries should be 
managed according to usual 
standard of care
Ensure all patients on OAT have 
a take-home naloxone kit and 
are trained on its use along 
with other harm reduction 
strategies
• Patient and carer education
• Access to Take Home Naloxone
• Engage carers in overseeing use 
of medications where possible
• Regularly review patient 
conditions and use of 
medications
• Document decision making 
regarding TADs and risk 
mitigation strategies.
Communicat e with staff at 
dosing point.
• Confer with a colleague if in 
doubt
• Inform other key service 
providers of changes in 
treatment conditions, including 
the number of TADs in writing.
• Provision of take-home naloxone
• Safe storage  boxes, especially if 
there  are children in the home
• Information sharing  with 
children’s social care and other 
relevant professionals
• Verbal and written harm reduction 
advice
• Regular communication between 
patient and service, enabled by 





• Consider using remote 
methods to provide care
• Review each patient’s 
case individually, taking 
into account stability, 
safety, storage, overdose 
risk, diversion risk, lapse 
or relapse, the dangers 
associated with COVID-19 and 
current public health advice 
around social distancing
• Record the decision-making 
process, any deviations from 
these or standard guidelines, 
and clinical justifications in 
the patient’s record
• Assume open ongoing 
communication with patient;  
if not possible remotely, it  
may be more appropriate to  
continue in-person care  using 
standard carry  parameters. 
• Should be done whenever 
possible to support physical 
distancing and reduce overall 
risks
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Resources Listing
Below is a list of online resources on substance use. Please note that this is not an exhaustive list of 
resources.
Clinical Support Resources for Patients and Healthcare 
Providers
Anxiety Canada’s free MindShift™ CBT app 
This app focuses on assisting in the management of anxiety using scientifically proven strategies (free 
for iOS and Android devices) 
British Columbia Centre on Substance Use: COVID‑19
Canadian Addiction Counsellors Certification Federation
Virtual addiction counselling
CATIE – Canada’s source for HIV and hepatitis C information
College of Physicians and Surgeons of Newfoundland and Labrador ‑ Opioid Agonist Treatment 
(OAT) Guidance during COVID‑19
Community Addictions Peers Support Association (CAPSA) and Breaking Free Online
In response to COVID-19 and the increased risks for those with substance use disorders, the Community 
Addictions Peers Support Association (CAPSA) has partnered with Breaking Free Online to provide 
free access to Canadians (service code CAPSA2020)
Draft Emergency Carry Agreement 
Nova Scotia Department of Health and Wellness: Points to Guide Clinical Decision for OAT Prescribers
Nova Scotia Health Authority (NSHA) Standard Operating Procedures for Opioid Use Disorder 
Treatment (OUDT) Programs
Documents included: Overview and Infection Control Practices SOP, New Admissions and Transfers 
SOP, Ongoing Client Being Prescribed Methadone SOP, and Clients in Self-Isolation or Quarantine SOP.
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Providence Health Care Nursing Practice Standard Dispensing Injectable Opioid Agonist Therapy to 
Client With or at Risk of COVID‑19
SMART Recovery Program 
This website includes message boards, chat rooms, online meetings, and an online library of recovery 
resources
Take Home Naloxone
Free online naloxone training 
Toward the Heart
Free online naloxone training
Harm Reduction Resources
Canadian Association of People Who Use Drugs (CAPUD) 
Canadian Drug Policy Coalition: COVID‑19 Harm Reduction Resources
International Network of People Who Used Drugs: COVID‑19 Crisis: Harm Reduction Resources for 
People who Use Drugs
Mental Health and Substance Use Resources 
Centre for Addiction and Mental Health (CAMH): Mental Health and the COVID‑19 Pandemic
Narcotics Anonymous
Taking Care of Your Mental Health (COVID‑19)
Wellness Together Canada: Mental Health and Substance Use Support
Indigenous Communities
Assembly of First Nations: COVID‑19
First Nations Health Managers Association: COVID‑19 Resources and Announcement
Up-to-date information on COVID-19
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First Peoples Wellness Circle: COVID‑19 Resources page
Provides printable Information Sheets for Mental Wellness for Community; Parents and Children; 
Elders and Seniors; and Health Professionals
Thunderbird Partnership Foundation: Harm Reduction during COVID‑19
Support Resources for Healthcare Providers
Canadian Foundation for Healthcare Improvement (CFHI)
Supports partners to accelerate the identification, spread and scale of proven healthcare innovations. 
Webinar Series: Patient Partnership in a Time of COVID-19
Health Canada Subsection 56(1) Class Exemption for Patients, Practitioners and Pharmacists 
Prescribing and Providing Controlled Substances in Canada during the Coronavirus Pandemic 
In response to the evolving health risk due to COVID-19, to maintain Canadians’ access to controlled 
substances for medical treatments (e.g. treatment of substance use disorders and chronic pain), while 
they adhere to social distancing guidance from public health officials or if they need to self-isolate, 
Health Canada has issued exemptions for prescriptions of controlled substances under the Controlled 
Drugs and Substances Act (CDSA) and its Regulations.
Mental Health First Aid Canada
Resource hub which provides credible information and resources for mental health for the Healthcare 
professionals “Resources for Healthcare Sector” 
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Appendix 5: Health Canada Tool Kit
Health Canada has compiled a number of resources in an effort to provide clarity regarding the rules 
that apply for substance use disorder treatment or providing a pharmaceutical grade alternative to 
the toxic street supply in Canada, in the context of COVID-19. This includes:
• A regulatory pathways graphic;
• Frequently asked questions and answers related to the legislative and regulatory requirements 
for substance use disorder treatment/safer supply;
• A list of all relevant exemptions that have been issued under the Controlled Drugs and 
Substances Act; 
• Formulary coverage under drug plans of medications used in substance use disorder treatment 
and as pharmaceutical grade alternatives to the illegal supply; and, 
• Resources related to substance use disorder treatment and providing safer supply, both in 
general and during the COVID-19 pandemic.
https://www.dropbox.com/sh/x622qndzvmydsvm/AABi888G_Ase6T0-N1Pd3uboa?dl=0
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